Photo of Laura Spring,  MD

Laura Spring, MD

Massachusetts General Hospital

Massachusetts General Hospital
Phone: (617) 726-6500
Fax: (617) 724-1079

Laura Spring, MD

Massachusetts General Hospital

EDUCATIONAL TITLES

  • Instructor, Medicine, Harvard Medical School
  • Attending Physician, Medical Oncology, Massachusetts General Hospital

DF/HCC PROGRAM AFFILIATION

Research Abstract

Dr. Spring is a clinical/translational investigator and breast medical oncologist at the Massachusetts General Hospital Cancer Center and Harvard Medical School. The primary focus of her research is to develop novel therapeutic and biomarker strategies to improve the care of breast cancer patients. She is particularly interested in blood-based monitoring of localized breast cancer and the use of targeted therapies in the neoadjuvant setting. Dr. Spring is the recipient of a Young Investigator Award from the ASCO Conquer Cancer Foundation for her work exploring circulating tumor cell (CTC) monitoring in the neoadjuvant setting in breast cancer. She is involved with the design and conduct of several breast cancer clinical trials for localized and metastatic breast cancer.

Publications

Powered by Harvard Catalyst
  • Drago JZ, Formisano L, Juric D, Niemierko A, Servetto A, Wander SA, Spring LM, Vidula N, Younger J, Peppercorn J, Yuen M, Malvarosa G, Sgroi D, Isakoff SJ, Moy B, Ellisen LW, Iafrate AJ, Arteaga CL, Bardia A. Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR) Breast Cancer. Clin Cancer Res 2019. PubMed
  • Wander SA, Spring LM, Bardia A. Genetics to epigenetics: targeting histone deacetylases in hormone receptor-positive metastatic breast cancer. Lancet Oncol. 2019; 20:746-748. PubMed
  • Goel S, Pernas S, Tan-Wasielewski Z, Barry WT, Bardia A, Rees R, Andrews C, Tahara RK, Trippa L, Mayer EL, Winer EP, Spring LM, Tolaney SM. Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial. Clin Breast Cancer 2019. PubMed
  • Spring LM, Wander SA, Zangardi M, Bardia A. CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions. Curr Oncol Rep 2019; 21:25. PubMed
  • Medford AJ, Dubash TD, Juric D, Spring L, Niemierko A, Vidula N, Peppercorn J, Isakoff S, Reeves BA, LiCausi JA, Wesley B, Malvarosa G, Yuen M, Wittner BS, Lawrence MS, Iafrate AJ, Ellisen L, Moy B, Toner M, Maheswaran S, Haber DA, Bardia A. Blood-based monitoring identifies acquired and targetable driver mutations in endocrine-resistant metastatic breast cancer. NPJ Precis Oncol 2019; 3:18. PubMed
  • Keklikoglou I, Cianciaruso C, Güç E, Squadrito ML, Spring LM, Tazzyman S, Lambein L, Poissonnier A, Ferraro GB, Baer C, Cassará A, Guichard A, Iruela-Arispe ML, Lewis CE, Coussens LM, Bardia A, Jain RK, Pollard JW, De Palma M. Chemotherapy elicits pro-metastatic extracellular vesicles in breast cancer models. Nat Cell Biol 2019. PubMed
  • Zangardi ML, Spring LM, Nagayama A, Bardia A. Sacituzumab for the treatment of triple-negative breast cancer: is this the poster child of future therapy? Expert Opin Investig Drugs 2018. PubMed
  • Kwan TT, Bardia A, Spring LM, Giobbie-Hurder A, Kalinich M, Dubash T, Sundaresan T, Hong X, LiCausi JA, Ho U, Silva EJ, Wittner BS, Sequist LV, Kapur R, Miyamoto DT, Toner M, Haber DA, Maheswaran S. A Digital RNA Signature of Circulating Tumor Cells Predicting Early Therapeutic Response in Localized and Metastatic Breast Cancer. 2018; 8:1286-1299. PubMed
  • Spring L, Niemierko A, Haddad S, Yuen M, Comander A, Reynolds K, Shin J, Bahn A, Brachtel E, Specht M, Smith BL, Taghian A, Jimenez R, Peppercorn J, Isakoff SJ, Moy B, Bardia A. Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer. Breast Cancer Res Treat 2018. PubMed
  • Spring L, Bardia A. Cycling Toward Progress: Ribociclib, a CDK 4/6 Inhibitor for Breast Cancer. Clin Cancer Res 2018; 24:2981-2983. PubMed
  • Karagounis T, Vallurupalli M, Nathan N, Nazarian R, Vedak P, Spring L, Chen ST. Stevens-Johnson syndrome-like eruption from palbociclib in a patient with metastatic breast cancer. JAAD Case Rep 2018; 4:452-454. PubMed
  • Abraham E, Post K, Spring L, Malvarosa G, Tripp E, Peppercorn JM, Bardia A, Habin K. Research Biopsies: An Integrative Review of the Experiences of Patients With Cancer. 2018; 22:E71-E77. PubMed
  • Spring L, Greenup R, Niemierko A, Schapira L, Haddad S, Jimenez R, Coopey S, Taghian A, Hughes KS, Isakoff SJ, Ellisen LW, Smith BL, Specht M, Moy B, Bardia A. Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer. J Natl Compr Canc Netw 2017; 15:1216-1223. PubMed
  • Zangardi ML, Spring LM, Blouin GC, Bardia A. Ribociclib for post-menopausal women with HR+/HER2- advanced or metastatic breast cancer. Expert Rev Clin Pharmacol 2017. PubMed
  • Spring LM, Zangardi ML, Moy B, Bardia A. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations. Oncologist 2017; 22:1039-1048. PubMed
  • Spring LM, Marshall MR, Warner ET. Mammography decision making: Trends and predictors of provider communication in the Health Information National Trends Survey, 2011 to 2014. Cancer 2016; 123:401-409. PubMed
  • Crombie J, Spring L, Li S, Soiffer RJ, Antin JH, Alyea EP, Glotzbecker B. Readmissions after Umbilical Cord Blood Transplantation and Impact on Overall Survival. Biol Blood Marrow Transplant 2016; 23:113-118. PubMed
  • Bychkovsky BL, Guo H, Sutton J, Spring L, Faig J, Dagogo-Jack I, Battelli C, Houlihan MJ, Yeh TC, Come SE, Lin NU. Use and Yield of Baseline Imaging and Laboratory Testing in Stage II Breast Cancer. Oncologist 2016. PubMed
  • Spring LM, Gupta A, Reynolds KL, Gadd MA, Ellisen LW, Isakoff SJ, Moy B, Bardia A. Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis. JAMA Oncol 2016. PubMed
  • Spring L, Bardia A, Modi S. Targeting the cyclin D-cyclin-dependent kinase (CDK) 4/6-retinoblastoma pathway with selective CDK 4/6 inhibitors in hormone receptor-positive breast cancer: rationale, current status, and future directions. Discov Med 2016; 21:65-74. PubMed
  • Spring L, Li S, Soiffer RJ, Antin JH, Alyea EP, Glotzbecker B. Risk factors for readmission after allogeneic hematopoietic stem cell transplantation and impact on overall survival. Biol Blood Marrow Transplant 2015; 21:509-16. PubMed
  • Spring L, Robillard D, Gehlbach L, Simas TA. Impact of pass/fail grading on medical students' well-being and academic outcomes. Med Educ 2011; 45:867-77. PubMed
Hide